Comparative Pharmacology
Head-to-head clinical analysis: GVS versus NEOMYCIN SULFATE POLYMYXIN B SULFATE HYDROCORTISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GVS versus NEOMYCIN SULFATE POLYMYXIN B SULFATE HYDROCORTISONE.
GVS vs NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GVS is not a recognized drug. No mechanism of action available.
Neomycin sulfate is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis in susceptible bacteria. Polymyxin B sulfate is a polypeptide antibiotic that disrupts bacterial cell membrane integrity by interacting with phospholipids. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating immune cell activity.
1 mg IV bolus every 3 minutes up to 3 doses as needed for status epilepticus; max total dose 3 mg.
Otic: Instill 3-5 drops into the affected ear(s) 3-4 times daily; for acute otitis externa, a wick may be used initially.
None Documented
None Documented
Terminal half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Neomycin: 2-3 hours (renal impairment: up to 12-24 hours). Polymyxin B: 4.5-6 hours (prolonged in renal failure). Hydrocortisone: 1.5-2 hours.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Neomycin is excreted primarily unchanged in feces (97%) after oral administration; absorbed fraction is renally excreted (30-50%). Polymyxin B is renally excreted (60%) with some biliary excretion. Hydrocortisone is metabolized hepatically and excreted renally as conjugates.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic